RT Journal Article
SR Electronic
T1 A Systematic Review of COVID - 19 Induced Myocarditis - Symptomatology, Prognosis, and Clinical Findings
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.29.21258059
DO 10.1101/2021.05.29.21258059
A1 Jaiswal, Vikash
A1 Nagpal, Shavy
A1 Labitag, Christine Angela E.
A1 Tayo, Janelle
A1 Patel, Abhinav
A1 Lo, Kevin Bryan
A1 Vijayan, Rupalakshmi
A1 Matos, Wanessa F
A1 Yaqoob, Sadia
A1 Panday, Priyanka
A1 Savani, Saloni
A1 Alnahas, Zeinab
A1 Bhatnagar, Arushee
A1 Diaz, Yoandra
A1 Dylewski, John R.
YR 2021
UL http://medrxiv.org/content/early/2021/06/02/2021.05.29.21258059.abstract
AB Objective With the advent of a novel coronavirus in December 2019, several case studies have reported its adversity on cardiac cells. We conducted a systematic review that describes the symptomatology, prognosis, and clinical findings of patients with COVID-19-related myocarditis.Methods Search engines including PubMed, Google Scholar, Cochrane Central, and Web of Science were queried for “SARS-CoV-2” or “COVID 19” and “myocarditis.” PRISMA guidelines were employed, and peer-reviewed journals in English related to COVID-19 were included.Results This systematic review included 22 studies and 37 patients. Eight patients (36%) were confirmed myocarditis, while the rest were possible myocarditis. Most patients had elevated cardiac biomarkers, including troponin, CRP, CK, CK-MB, and NT-pro BNP. Electrocardiogram results noted tachycardia (47%), left ventricular hypertrophy (50%), ST-segment alterations (41%), and T wave inversion (18%). Echocardiography presented reduced LVEF (77%), left ventricle abnormalities (34%), right ventricle aberrations (12%), and pericardial effusion (71%). Further, CMR showed reduced myocardial edema (75%), non-ischemic patterns (50%), and hypokinesis (26%). The mortality was significant at 25%.Conclusions Mortality associated with COVID-19 myocarditis appears significant but underestimated. Further studies are warranted to evaluate and quantify patients’ actual prognosis and outcomes with COVID-19 myocarditis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors have not declared a specific grant for this research from any funding agency in public, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a systemetic review so dont need ethical approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesavailable on requestS/Ssigns and symptomsHTNhypertensionDM IItype II diabetes mellitusRArheumatoid arthritisNA-Notavailable